Latest life-extending cancer drug 'rationed by postcode': Dozens of hospitals refuse to hand out treatments
Hospitals are denying patients the latest life-extending cancer drugs, a report reveals.
Dozens of trusts are failing to hand out treatments for bowel, ovarian, lung and brain cancer that have been approved by the NHS watchdog NICE. Some of these drugs have been shown to boost survival rates by a quarter while others have extended the lives of terminally-ill patients by over a year.
The report - commissioned by the Department of Health - also reveals that many hospitals are failing to prescribe the latest treatments for heart attacks, asthma, multiple sclerosis, arthritis and Crohn’s Disease.
In fact some of the drugs were approved for use by NICE more than seven years ago.
Click here to read more.
- Jun 2021 (1)
- Feb 2020 (1)
- Apr 2018 (1)
- Mar 2018 (1)
- Jan 2018 (3)
- Dec 2017 (5)
- Nov 2017 (7)
- Oct 2017 (8)
- Sep 2017 (8)
- Aug 2017 (4)
- Jul 2017 (5)
- Jun 2017 (5)
- May 2017 (3)
- Apr 2017 (3)
- Mar 2017 (4)
- Feb 2017 (2)
- Jan 2017 (1)
- Dec 2016 (5)
- Nov 2016 (8)
- Oct 2016 (7)
- Sep 2016 (2)
- Aug 2016 (6)
- Jul 2016 (6)
- Jun 2016 (1)
- A Career in Care - Jessica's Story
- Routes Blog 2020!
- Liverpool CQC inspection achieves a Good
- A huge THANK YOU to all our fantastic field and branch staff!
- Recruitment Opportunity in Newcastle
- Preston has moved
- Tameside's Christmas Toy Collection
- Certificate of Inspiration
- Tameside receive an OUTSTANDING in Care
Most Popular Posts
- Healthcare Assistants wanted in Blackpool to care for a gentleman and lady with spinal injuries
- Mental Health campaign receives additional funding
- Routes Healthcare need experienced childminders across the North West of England
- Accounts & Payroll Trainee Vacancy Routes Healthcare - Macclesfield
- Social Worker Struck Off
- Routes Healthcare Blackpool is committed to the modern apprenticeship scheme
- Routes Childcare - The local company with the Worldwide experience!
- Cancer 'Smart Bomb' Successfully Tested in US
- Personalisation 'at high risk of failure', Norman Lamb told